EpiVax is a bioinformatics and vaccine design company dedicated to the development and implementation of computational immunology tools to benefit the biotechnology industry. They recently received a grant for $390,000 from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to optimize delivery of an HIV vaccine.

EpiVax has extensive immunology and micro-biology laboratory capabilities including the most sophisticated MHC binding assays on the market. CEO/CSO, Dr. Annie De Groot, is a pioneer in the field of deimmunizing protein therapeutics and has accumulated several awards recognizing her medical innovations.